Two months earlier than expected, the US Food and Drug Administration (FDA) has greenlighted the use of Merck & Co’s multi-indication cancer treatment Keytruda in combination with Pfizer’s Inlyta as a treatment for previously untreated advanced renal cell carcinoma.
Original Article: FDA Approves US Merck-Pfizer Cancer Treatment